PROK2 and Parkinson disease: We utilized the small-molecule PK2 receptor antagonist PKRA7 (ref. 22) to block PK2 signalling in the MPTP model of PD because knockout mice for PK2 and its receptors show significant defects in brain development and architecture, potentially involving dopamine pathways that would confound our studies1, 3, 5, 6.